LALINDEN ADVISORS LP

Institutional investor · Portfolio as of Q1 2019

Top Holdings134 positions

Checking export access…
Activity:
205.8M$337.1M7.7%——
1 qtr
First report
0
291.4M$321.3M7.4%——
1 qtr
First report
0
AABAAABADelisted
Fund

ALTABA INC

3.8M$278.7M6.4%——
1 qtr
First report
0
??TELADOC HEALTH INCDelisted
Bond
138.4M$206M4.7%———
First report
0
??H WORLD GROUP LTDDelisted
Bond
158.3M$182M4.2%——
1 qtr
First report
0
155.4M$151.7M3.5%——
1 qtr
First report
0
73.6M$133M3.0%——
1 qtr
First report
0
??EVERBRIDGE INCDelisted
Bond
57.8M$130.9M3.0%———
First report
0
??RINGCENTRAL INCDelisted
Bond
84.8M$120.8M2.8%———
First report
0
??OKTA INCDelisted
Bond
64.5M$117M2.7%———
First report
0
??WAYFAIR INCDelisted
Bond
56.6M$86.8M2.0%———
First report
0
??EXACT SCIENCES CORPDelisted
Bond
60.9M$83.3M1.9%——
1 qtr
First report
0
??CTRIP COM INTL LTDDelisted
Bond
80.8M$82M1.9%———
First report
0
??INNOVIVA INCDelisted
Bond
74.9M$80.3M1.8%——
1 qtr
First report
0
??COLONY CAPITAL INCDelisted
Bond
81.4M$78.4M1.8%——
1 qtr
First report
0
75.1M$73.8M1.7%——
1 qtr
First report
0
??VECTOR GROUP LTDDelisted
Bond
64.3M$65.5M1.5%———
First report
0
63.9M$64.9M1.5%——
1 qtr
First report
0
36.5M$64.2M1.5%———
First report
0
62.7M$61.1M1.4%——
1 qtr
First report
0
$4.4B
AUM
134
Positions
Q1 2019
Filing
HI score · 2.5/5
Quarterly 13F Value Change
Not enough history yet
Activity profile
Q1'19

First report: nothing earlier to compare

Composition
Equity vs derivatives
Equity99%Puts0%Calls1%
Holding period
<1Q100%1-4Q0%1-2Y0%2Y+0%

LINDEN ADVISORS LP manages $4.4B across 134 positions as of Q1 2019. Top holdings: MICROCHIP TECHNOLOGY INC (7.7%), MICROCHIP TECHNOLOGY INC (7.4%), AABA (6.4%). Fund DNA: Momentum Trader. HoldingsIntel Score: 2.5/5.0.

Q1 2019 Summary

First quarter we have for this fund: 134 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $4.4B across 134 positions.

Top holdings by portfolio weight

Total AUM$4B
MICROCHIP TE7.71%
MICROCHIP TE7.35%
AABA6.38%
TELADOC HEAL4.71%
H WORLD GROU4.16%
APOLLO CMMRL3.47%
SAREPTA THER3.04%
EVERBRIDGE I2.99%
RINGCENTRAL 2.76%
OKTA INC2.68%
Other1.99%

Portfolio allocation by GICS sector

Sectors7
Unknown87.08%
Consumer Cyclical5.82%
Financial Services2.50%
Technology1.65%
Industrials1.55%
Real Estate1.19%
Healthcare0.21%

Behavioral investing profile

Checking access…
Momentum Trader
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L57
Conviction31
Concentration37
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BR10806XAD4BRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+151.4M shares+$192.5M
7Q
VI928298AR9VISHAY INTERTECHNOLOGY INC.
Q4 2024 → Q2 2026+353.9M shares+$770.5M
4Q
CO19459JAC8COLLEGIUM PHARMACEUTICAL INC
Q3 2025 → Q2 2026+26.6M shares+$50.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used